Malaria mRNA Vaccine2022-06-10T06:19:04+00:00

Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans.

About Malaria mRNA Vaccine

People who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. Four kinds of malaria parasites infect humans: Plasmodium falciparum, P. vivax, P. ovale, and P. malariae. In addition, P. knowlesi, a type of malaria that naturally infects macaques in Southeast Asia, also infects humans, causing malaria that is transmitted from animal to human (“zoonotic” malaria). P. falciparum is the type of malaria that is most likely to result in severe infections and if not promptly treated, may lead to death. Although malaria can be a deadly disease, illness and death from malaria can usually be prevented.

Source: CDC

In 2020, there were an estimated 241 million cases of malaria worldwide. Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. The estimated number of malaria deaths stood at 627 000 in 2020. The WHO African Region carries a disproportionately high share of the global malaria burden. In 2020, the region was home to 95% of malaria cases and 96% of malaria deaths. Children under 5 accounted for about 80% of all malaria deaths in the Region.

Source: WHO

Malaria mRNA Vaccine Pipeline

DEVELOPMENT

PRECLINCAL

PHASE 1

PHASE 2

PHASE 3

INDICATION
Malaria mRNA Vaccine (Malaria-mRNA)

GLOBAL PUBLIC HEALTH IMPACT
Prophylactic mRNA Vaccine. Therapeutic mRNA Vaccine

PARTNERS / SUPPORTERS
mRNA UCV Consortium

COMMERCIAL
Normax

LICENSING
Vaxcomm

Malaria mRNA Vaccine Pipeline

DEVELOPMENT

INDICATION
Malaria mRNA Vaccine

TECHNOLOGY
Prophylactic mRNA Vaccine. Therapeutic mRNA Vaccine

PARTNERS / SUPPORTERS
mRNA UCV Consortium

COMMERCIAL
Normax

LICENSING
Vaxcomm

Pricing

Our goal is to mass-produce a vaccine that is both highly efficient and affordable for the general public, that we will be able to distribute at the cost of only $4 per dose.

The median financial cost of diagnosing a case of malaria was $4.32 (range $0.34-$9.34). The median financial cost of treating an episode of uncomplicated malaria was $5.84 (range $2.36-$23.65) and the median financial cost of treating an episode of severe malaria was $30.26 (range $15.64-$137.87).

Source: BMC Malaria Journal

Go to Top